On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Preclinical research compound.
ERR signaling
The experiments examined ERRα, ERRβ, and ERRγ activation and an ERRα-dependent aerobic-exercise response. [1]
What the evidence shows
Exercise-related laboratory findings
A mouse study found changes in oxidative muscle fibers and improved endurance after SLU-PP-332 exposure. This tested selected exercise-related pathways, not all benefits of exercise. [1]
Metabolic mouse models
A separate experiment reported reduced fat mass in mouse obesity models. It provides a reason for further research, not proof of a human weight-management treatment. [2]
What remains unknown
Human benefits, interactions, and long-term safety are not established by these experiments. An exercise-like gene signature is not proof that a medicine replaces physical activity.
Safety
Safety remains uncharacterized in this evidence
The cited efficacy experiments are preclinical. They do not determine a safe human exposure or identify uncommon human toxicities. [2]
Oral claims need evidence
The SLU-PP-915 study describes SLU-PP-332 as lacking oral bioavailability. This distinction matters when evaluating capsules marketed under the earlier name. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is SLU-PP-915 the same compound?
No. The later paper describes SLU-PP-915 as a chemically distinct molecule; results for it should not be assigned to SLU-PP-332.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity2023 · Primary research · PubMed
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome2024 · Primary research · PubMed
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity2025 · Primary research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.